Advertisement
BBLG vs DNA
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BBLG is a StrongBuy and DNA is a Buy.
BBLG's RSI Indicator climbs out of oversold territory
The RSI Oscillator for BBLG moved out of oversold territory on November 09, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 47 similar instances when the indicator left oversold territory. In 40 of the 47 cases the stock moved higher. This puts the odds of a move higher at 85%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Moving Average Convergence Divergence (MACD) for BBLG just turned positive on November 09, 2026. Looking at past instances where BBLG's MACD turned positive, the stock continued to rise in 30 of 39 cases over the following month. The odds of a continued upward trend are 77%.
Following a +6.12% 3-day Advance, the price is estimated to grow further. Considering data from situations where BBLG advanced for three days, in 145 of 176 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
BBLG may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 30, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BBLG as a result. In 83 of 87 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BBLG declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for BBLG entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 7 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 33 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.234) is normal, around the industry mean (3.498). P/E Ratio (-1.191) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 92 (best 1 - 100 worst), indicating slightly worse than average price growth. BBLG’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BBLG’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
DNA sees its Stochastic Oscillator ascends from oversold territory
On November 04, 2026, the Stochastic Oscillator for DNA moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 68 instances where the indicator left the oversold zone. In 62 of the 68 cases the stock moved higher in the following days. This puts the odds of a move higher at over 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 03, 2026. You may want to consider a long position or call options on DNA as a result. In 72 of 87 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 83%.
The Moving Average Convergence Divergence (MACD) for DNA just turned positive on November 10, 2026. Looking at past instances where DNA's MACD turned positive, the stock continued to rise in 40 of 51 cases over the following month. The odds of a continued upward trend are 78%.
The 50-day moving average for DNA moved above the 200-day moving average on October 07, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Following a +24.20% 3-day Advance, the price is estimated to grow further. Considering data from situations where DNA advanced for three days, in 209 of 248 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
Bearish Trend Analysis
The 10-day RSI Indicator for DNA moved out of overbought territory on October 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 24 similar instances where the indicator moved out of overbought territory. In 20 of the 24 cases, the stock moved lower in the following days. This puts the odds of a move lower at 83%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where DNA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for DNA entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating steady price growth. DNA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 41 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.809) is normal, around the industry mean (3.498). P/E Ratio (-2.258) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (3.397) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 90 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DNA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
BBLG | ||
|---|---|---|
OUTLOOK RATING 1..100 | 55 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 33 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | |
SMR RATING 1..100 | 98 | |
PRICE GROWTH RATING 1..100 | 92 | |
P/E GROWTH RATING 1..100 | 7 | |
SEASONALITY SCORE 1..100 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| BBLG | DNA | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 85% | 7 days ago 83% |
| Stochastic ODDS (%) | 2 days ago 84% | 2 days ago 90% |
| Momentum ODDS (%) | 2 days ago 90% | 2 days ago 83% |
| MACD ODDS (%) | 2 days ago 77% | 2 days ago 78% |
| TrendWeek ODDS (%) | 2 days ago 90% | 2 days ago 85% |
| TrendMonth ODDS (%) | 2 days ago 90% | 2 days ago 88% |
| Advances ODDS (%) | 3 days ago 82% | 3 days ago 84% |
| Declines ODDS (%) | 9 days ago 90% | 10 days ago 90% |
| BollingerBands ODDS (%) | 2 days ago 84% | N/A |
| Aroon ODDS (%) | 2 days ago 90% | 2 days ago 90% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BBLG’s FA Score shows that 2 FA rating(s) are green while DNA’s FA Score has 0 green FA rating(s).
- BBLG’s FA Score: 2 green, 3 red.
- DNA’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BBLG’s TA Score shows that 5 TA indicator(s) are bullish while DNA’s TA Score has 5 bullish TA indicator(s).
- BBLG’s TA Score: 5 bullish, 3 bearish.
- DNA’s TA Score: 5 bullish, 3 bearish.
Price Growth
BBLG (@Biotechnology) experienced а -3.48% price change this week, while DNA (@Biotechnology) price change was +11.62% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was -2.72%, and the average quarterly price growth was -13.41%.
Reported Earning Dates
BBLG is expected to report earnings on Mar 03, 2027.
DNA is expected to report earnings on Mar 04, 2027.
Industries' Descriptions
@Biotechnology (+4.90% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
BBLG and
Correlation & Price change
A.I.dvisor tells us that BBLG and DYAI have been poorly correlated (+27% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that BBLG and DYAI's prices will move in lockstep.
| Ticker / NAME | Correlation To BBLG | 1D Price Change % | ||
|---|---|---|---|---|
| BBLG | 100% | -0.67% | ||
| DYAI - BBLG | 27% Poorly correlated | -3.84% | ||
| NTLA - BBLG | 26% Poorly correlated | -7.76% | ||
| RXST - BBLG | 25% Poorly correlated | +0.82% | ||
| PSNL - BBLG | 25% Poorly correlated | -0.44% | ||
| DNA - BBLG | 25% Poorly correlated | -2.91% | ||
More | ||||
DNA and
Correlation & Price change
A.I.dvisor indicates that over the last year, DNA has been loosely correlated with TWST. These tickers have moved in lockstep 63% of the time. This A.I.-generated data suggests there is some statistical probability that if DNA jumps, then TWST could also see price increases.
| Ticker / NAME | Correlation To DNA | 1D Price Change % | ||
|---|---|---|---|---|
| DNA | 100% | -2.91% | ||
| TWST - DNA | 63% Loosely correlated | -2.37% | ||
| RXRX - DNA | 61% Loosely correlated | -6.70% | ||
| VCYT - DNA | 58% Loosely correlated | -7.18% | ||
| ABSI - DNA | 53% Loosely correlated | -7.69% | ||
| NTLA - DNA | 53% Loosely correlated | -7.76% | ||
More | ||||